Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.700
0.00 (0.00%)
At close: Apr 14, 2026, 4:00 PM EDT
1.690
-0.010 (-0.59%)
After-hours: Apr 14, 2026, 4:00 PM EDT

Chemomab Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
3.733.417.0811.566.03
Research & Development
5.8311.3318.3816.986.33
Operating Expenses
9.5714.7425.4628.5312.37
Operating Income
-9.57-14.74-25.46-28.53-12.37
Interest Expense
-----0.11
Interest & Investment Income
0.450.791.240.35-
Currency Exchange Gain (Loss)
0.130.01---
Pretax Income
-9-13.95-24.22-28.18-12.48
Income Tax Expense
----0.53-
Net Income
-9-13.95-24.22-27.65-12.48
Net Income to Common
-9-13.95-24.22-27.65-12.48
Shares Outstanding (Basic)
64333
Shares Outstanding (Diluted)
64333
Shares Change (YoY)
42.10%52.79%3.26%9.70%51.71%
EPS (Basic)
-1.41-3.11-8.25-9.72-4.81
EPS (Diluted)
-1.41-3.11-8.25-9.72-4.81
Free Cash Flow
-11.13-15.39-23.61-20.44-12.61
Free Cash Flow Per Share
-1.75-3.43-8.04-7.18-4.86
EBITDA
-9.5-14.69-25.39-28.48-12.33
D&A For EBITDA
0.070.050.070.060.03
EBIT
-9.57-14.74-25.46-28.53-12.37
Updated Mar 19, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q